Overview

Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study was to evaluate the efficacy and safety of vonoprazan with different doses of amoxicillin for Helicobacter Pylori.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Treatments:
Amoxicillin
Criteria
Inclusion Criteria:

1. Ages between 18 and 70 years; Sexes eligible for study: both;

2. patients who are diagnosed with Helicobacter pylori with 13C urea breath test or 14C
urea breath test;

3. treatment-naive patients or patients who failed to eradicate Helicobacter pylori in
the past but haven't undergone eradication therapy in the past six months;

4. voluntary to be involved in the study and written informed consent was obtained from
all patients

Exclusion Criteria:

1. allergic reactions to the study drugs;

2. patients with peptic ulcer;

3. patients who underwent eradication therapy for Helicobacter pylori during the last six
months;

4. patients who took antibiotics,bismuth agents,probiotics within four weeks prior to
treatment and those who took H2 receptor antagonists,proton pump inhibitors(PPIs) or
potassium competitive acid blockers within two weeks prior to treatment;

5. patients who are taking glucocorticoids, non-steroidal anti-inflammatory drugs or
anticoagulants;

6. patients who have history of esophageal or gastric surgery;

7. pregnant or lactating women;

8. patients who have severe concurrent diseases such as
hepatic,cardiovascular,respiratory,renal disorders or malignancies;

9. Alcohol abusers

10. MALT lymphoma of stomach or malignant tumor